[{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"RHEACELL","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"allo-APZ2-OTS","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AOP Health \/ AOP Health","highestDevelopmentStatusID":"10","companyTruncated":"AOP Health \/ AOP Health"},{"orgOrder":0,"company":"AOP Health","sponsor":"RHEACELL","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"allo-APZ2-CVU","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"AOP Health \/ AOP Health","highestDevelopmentStatusID":"10","companyTruncated":"AOP Health \/ AOP Health"}]

Find Clinical Drug Pipeline Developments & Deals by AOP Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Under the agreement, AOP will commercialize Rheacell’s two stem cell products, Ebesanar and Amesanar, in Europe, Turkey, Israel and the MENA region.

                          Product Name : Ebesanar

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 27, 2025

                          Lead Product(s) : allo-APZ2-OTS

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase III

                          Recipient : RHEACELL

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The partnership aims to develop and deliver innovative cell therapies, Ebesanar and Amesanar for patients suffering from Butterfly Children’s Disease and Chronic Venous Wounds.

                          Product Name : Amesanar

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 27, 2025

                          Lead Product(s) : allo-APZ2-CVU

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Recipient : RHEACELL

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Rapiblyk (landiolol) is a β1-adrenergic receptor antagonist, small molecule drug candidate which is indicated for the treatment of supraventricular tachycardia.

                          Product Name : Rapiblyk

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 27, 2024

                          Lead Product(s) : Landiolol Hydrochloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : BESREMi (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon. It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi is designed to be self-administered subcutaneously...

                          Product Name : Besremi

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 13, 2022

                          Lead Product(s) : Ropeginterferon-Alpha-2B

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : BESREMi (Ropeginterferon alfa-2b) is long-acting, mono-pegylated proline interferon, unique pharmacokinetic properties new level of tolerability, designed to be conveniently self-administered subcutaneously with pen once every two weeks, or up to monthly...

                          Product Name : Besremi

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 13, 2022

                          Lead Product(s) : Ropeginterferon-Alpha-2B

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank